RESEARCH POSTER PRESENTATION DESIGN © 2015 www.PosterPresentations.com Bell's palsy is a rapid unilateral facial nerve paresis (weakness) or paralysis (complete loss of movement) of unknown cause. The condition leads to the partial or complete inability to voluntarily move facial muscles on the affected side of the face. Although typically self-limited, the facial paresis/paralysis that occurs in Bell's palsy may cause significant temporary oral incompetence and an inability to close the eyelid, leading to potential eye injury. Additional long-term poor outcomes do occur and can be devastating to the patient.1 Immune, infective and ischaemic mechanisms are all potential contributors to the development of Bell's palsy, but the precise cause remains unclear.2 The aims of treatment in the acute phase of Bell's palsy include strategies to speed recovery and to prevent corneal complications. Eye care includes eye patching and lubrication. Strategies to speed recovery include physical therapy, corticosteroids and antiviral agents.3 Inactivated vaccines against SARS-CoV-2 are being developed by several vaccine manufacturers. The inactivated COVID-19 vaccine Sinovac CoronaVac was developed by Sinovac. CoronaVac has been authorized as a 2-dose vaccine for individuals aged 18 years and older. Systemic adverse effects include: fatigue, fever, myalgia, diarrhoea, headache, cough, nausea, and vomiting. Local side effects include: pain, pruritus, swelling, redness, and induration.4 INTRODUCTION METHOD REFERENCES 1) Reginald F. Baugh et al. Clinical Practice Guideline: Bell’s Palsy. American Academy of Otolaryngology—Head and Neck Surgery Foundation. 2013; 149(3S) Pg1. 2) Eviston TJ, et al. Bell's palsy: aetiology, clinical features and multidisciplinary care J Neurol Neurosurg Psychiatry. 2015 86: Pg1356-1361. 3) J. M. K. Murthy et al. Bell's palsy: Treatment guidelines. Ann Indian Acad Neurol. 2011 Jul; 14(Suppl1): S70–S72. 4) World Health Organisation. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. 2021: Pg 21. 5) Bin-Yan Yu et al. Bell’s palsy after inactivated COVID-19 vaccination in a patient with history of recurrent Bell’s palsy: A case report. World J Clin Cases. 2021 Sep 26; 9(27): Pg8274–8279. The above image to the left shows loss of nasolabial fold and drooping of the left mouth corner. The image to the right was taken after full recovery of Bell’s Palsy. Ophthalmology Department, Hospital Kuala Lumpur Thivakar S (MD), Fatin S (MS Opthal) Bell’s Palsy Post Administration of COVID-19 Inactivated Vaccine DISCUSSION CONCLUSION To report a case of Bell’s Palsy occurring post vaccination. AIM CASE REPORT Case report. A 23 years old Malay lady presented with left sided facial weakness over the past 2 weeks associated with occasional tearing over the left eye. She had no comorbids. Upon further questioning, it was noted that patient was administered her first dose of COVID- 19 vaccination 3 weeks ago, which was 1 week prior to her presentation to the Ophthalmology clinic. Upon general examination of the patient, it was noted that there was lagophthalmos over the left eye with poor Bell’s phenomenon. There was also loss of nasolabial fold over the left side of her face. Loss of frontal wrinkling as well as drooping of the left mouth corner was also noted. However there were no other cranial nerve involvement. Patient had no peripheral neurological deficits. Upon ocular examination, it was noted that right eye vision was 6/9 and her left eye vision was 6/24. No RAPD. Anterior segment of her right eye was unremarkable. Left eye anterior segment examination shows minimal superficial punctate keratopathy inferiorly at the cornea. Both eyes’ intraocular pressure was normal. Dilated fundus examination of both eye was unremarkable. As patient was referred from the ENT Department for the above complaints, patient was already started on Oral Mecobalamin and a tapering dose of Oral Prednisolone to be taken over